MedTrace Logo

Intermediate IND Severe Illness COVID-19 CP

NCT04411602 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2025-12-19

No results posted yet for this study

Summary

Beyond supportive care, there are currently no proven therapeutic options for pneumonia due to coronavirus disease (COVID-19), the infection caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Human convalescent plasma is an option for treatment of COVID-19 and will be available when sufficient numbers of people have recovered. Such persons should have high titer neutralizing immunoglobulin-containing plasma.

Conditions

  • Severe Acute Respiratory Syndrome
  • COVID

Interventions

DRUG

SARS-CoV-2 plasma

To determine feasibility of convalescent plasma for treating patients in the ICU with COVID-19.

Sponsors & Collaborators

  • Henry Ford Health System

    lead OTHER

Principal Investigators

  • Shukri David, MD · Ascension Providence Hospital, Southfield Campus

  • Debra J Levan, DO · Ascension Macomb-Oakland Hospital, Warren Campus

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-07
Primary Completion
2021-04-07
Completion
2021-04-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04411602 on ClinicalTrials.gov